Stockreport

Allogene Therapeutics Initiates Pivotal Phase 2 Trial Investigating Cemacabtagene Ansegedleucel (cema-cel), an Allogeneic CAR T Product, as Part of First Line Treatment for Patients with L...

Allogene Therapeutics, Inc.  (ALLO) 
Last allogene therapeutics, inc. earnings: 2/27 04:30 am Check Earnings Report
PDF First Prospective Trial to Incorporate the Foresight Diagnostics's Investigational CLARITY ™ Test to Identify Patients with LBCL Who Have Minimal Residual Disease (MRD) [Read more]